Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Chadwick Williams"'
Autor:
Geoffrey C Nguyen, Shane M Devlin, Waqqas Afif, Brian Bressler, Steven E Gruchy, Gilaad G Kaplan, Liliana Oliveira, Sophie Plamondon, Cynthia H Seow, Chadwick Williams, Karen Wong, Brian M Yan, Jennifer Jones
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 28, Iss 5, Pp 275-285 (2014)
BACKGROUND: There is a paucity of published data regarding the quality of care of inflammatory bowel disease (IBD) in Canada. Clinical quality indicators are quantitative end points used to guide, monitor and improve the quality of patient care. In C
Externí odkaz:
https://doaj.org/article/252302f6ccd8421ea0fef8aea036d7e9
Autor:
Sanjay K. Murthy, Laura E. Targownik, John Marshall, Chadwick Williams, Jennifer Jones, Sophie Plamondon, Edward V. Loftus, Cynthia H. Seow, Usha Chauhan, Mark Borgaonkar, Grigorios I. Leontiadis, Jonathan B. Meddings, Brendan Halloran, Greg Rosenfeld, Alain Bitton, David A. Schwartz, Reena Khanna, A. Hillary Steinhart, Brian Bressler, Erin D. Kennedy, Waqqas Afif, Paul Moayyedi, Remo Panaccione, Charles N. Bernstein
Publikováno v:
Journal of the Canadian Association of Gastroenterology
Background & Aims Crohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::877e2a7e7384e337f35f0c0094629094
https://doi.org/10.1093/jcag/gwz019
https://doi.org/10.1093/jcag/gwz019
Autor:
John Marshall, Edouard Louis, Chadwick Williams, Peter Bossuyt, Laurent Peyrin-Biroulet, Guillaume Bouguen, Xavier Hébuterne, Karen Frost, Arnaud Bourreille, Denis Franchimont, Laurent Beaugerie, Greg Rosenfeld, Marc Ferrante, Ciara OʼShea, Subrata Ghosh
Publikováno v:
Inflammatory Bowel Diseases
Inflammatory bowel diseases, 23 (3
Inflammatory bowel diseases, 23 (3
Background: The Inflammatory bowel disease (IBD) Disability Index is a validated tool that evaluates functional status; however, it is used mainly in the clinical trial setting. We describe the use of an iterative Delphi consensus process to develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59dfe12e924619db40f3933cc7d915b9
https://doi.org/10.1097/mib.0000000000001033
https://doi.org/10.1097/mib.0000000000001033
Autor:
Michael H. Weisman, Thomas J. Learch, Dermot P.B. McGovern, Stephan R. Targan, Madhavi L Siddanthi, Dmitry Karayev, Anish Patel, Dalin Li, Chadwick Williams, Vineet S Rolston
Objectives Avascular necrosis (AVN) is associated with significant morbidity potentially causing severe pain and disability; patients with inflammatory bowel disease (IBD) have a higher prevalence of AVN compared with non-IBD populations. The purpose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c6f6fd4e6dbd642f41c51c3bb2d06eb
https://europepmc.org/articles/PMC6252167/
https://europepmc.org/articles/PMC6252167/
Autor:
Erin D. Kennedy, John Marshall, Brendan P. Halloran, Laura E. Targownik, Waqqas Afif, Greg Rosenfeld, Paul Moayyedi, Alain Bitton, Remo Panaccione, Charles N. Bernstein, Jennifer Jones, Mark Borgaonkar, Chadwick Williams, Jonathan B. Meddings, Usha Chauhan, Brian Bressler, Grigorios I. Leontiadis, Sophie Plamondon, Edward V. Loftus, Reena Khanna, David A. Schwartz, A. Hillary Steinhart, Cynthia H. Seow, Sanjay K. Murthy
Publikováno v:
Inflammatory bowel diseases. 25(1)
Background Fistulas occur in about 25% of patients with Crohn's disease (CD) and can be difficult to treat. The aim of this consensus was to provide guidance for the management of patients with perianal fistulizing CD. Methods A systematic literature
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f101c56a1edec879084e385c8a69ae0
https://pubmed.ncbi.nlm.nih.gov/30099529
https://pubmed.ncbi.nlm.nih.gov/30099529
Publikováno v:
Inflammatory bowel diseases. 25(1)
Thiopurine metabolite monitoring to proactively dose optimize to achieve therapeutic levels has not been used consistently, and it is unclear if this would lead to better outcomes. We aimed to compare 6-month outcomes between standard and optimized d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3506b4f2f77f3a718167436e94581126
https://pubmed.ncbi.nlm.nih.gov/29920603
https://pubmed.ncbi.nlm.nih.gov/29920603
Autor:
Waqqas Afif, Brian Yan, Steven E. Gruchy, Geoffrey C. Nguyen, Chadwick Williams, Brian Bressler, Karen Wong, Cynthia H. Seow, Gilaad G. Kaplan, Shane M. Devlin, Jennifer Jones, Liliana Oliveira, Sophie Plamondon
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 28, Iss 5, Pp 275-285 (2014)
BACKGROUND: There is a paucity of published data regarding the quality of care of inflammatory bowel disease (IBD) in Canada. Clinical quality indicators are quantitative end points used to guide, monitor and improve the quality of patient care. In C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6f5f64938e86d20731a812064f94ca6
https://doi.org/10.1155/2014/941245
https://doi.org/10.1155/2014/941245
Autor:
Nick Teleten, Andrew Ippoliti, Gary Silber, Antonio Quiros, Phillip Fleshner, Ghassan Wahbeh, Dermont P. B McGovern, Subramaniam Kugathasan, Jerome I. Rotter, Eric A. Vasiliauskas, Michael C. Stephens, Talin Haritunians, Carol J. Landers, Marla Dubinsky, Deepa Panikkath, Soonil Kwon, Iwona Wrobel, Sharmayne Farrior, Chadwick Williams, Ron Bahar, Kent D. Taylor, Stephan R. Targan
Publikováno v:
Inflammatory Bowel Diseases. 19:1662-1670
Background The ability to identify patients with Crohn's disease (CD) at highest risk of surgery would be invaluable in guiding therapy. Genome-wide association studies have identified multiple IBD loci with unknown phenotypic consequences. The aims
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88cf94d9b75ed105fd723ac189a6f2bc
https://doi.org/10.1097/mib.0b013e318281f275
https://doi.org/10.1097/mib.0b013e318281f275
Publikováno v:
Therapeutic advances in gastroenterology. 4(4)
Mesalazine [5-aminosalicylic acid (5-ASA)] has been used for over 30 years in the treatment of inflammatory bowel disease (IBD). It is a highly effective, safe, and well-tolerated drug for treatment of mild to moderate ulcerative colitis, which repre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33932fa6215158b23697a96bd167dfd1
https://pubmed.ncbi.nlm.nih.gov/21765868
https://pubmed.ncbi.nlm.nih.gov/21765868
Autor:
Remo Panaccione, Cynthia H. Seow, Gert Van Assche, Chadwick Williams, Geoffrey C. Nguyen, Richard N. Fedorak, Shane M. Devlin, Francis Tse, Edmond-Jean Bernard, John Marshall, Brian Bressler, Richmond Sy, Laurent Peyrin-Biroulet, Waqqas Afif, Mark Borgaonkar, Jennifer Jones, Peter Thomson, Robert M Penner, Charles N. Bernstein, Grigorios I. Leontiadis, Alain Bitton, Laura E. Targownik, Walter Reinisch, Brian G. Feagan, A. Hillary Steinhart
Publikováno v:
Gastroenterology. 148:1035-1058.e3
Background & Aims The medical management of ulcerative colitis (UC) has improved through the development of new therapies and novel approaches that optimize existing drugs. Previous Canadian consensus guidelines addressed the management of severe UC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db66e1474a82f4ab1e924c371f547425
https://doi.org/10.1053/j.gastro.2015.03.001
https://doi.org/10.1053/j.gastro.2015.03.001